drugset / Trial / NCT05903183
A Study to Evaluate the Safety and Immunogenicity of IVX-A12 in Participants of 60 to 85 Years of Age
RandomizedParallel-groupQuadruple-blindOther
Summary
The primary purpose of the study is to assess the safety, tolerability and immunogenicity of a bivalent respiratory syncytial virus (RSV)/human metapneumovirus (hMPV) virus-like particle (VLP) candidate vaccine (IVX-A12) compared to placebo, when administered as a single-dose regimen in healthy older adults 60 to 85 years of age.
Timeline
- Start
- 2023-05-15
- Primary completion
- 2023-06-05
- Completion
- 2024-10-25
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | IVX-A12 | Vaccine | — | Intramuscular |
Indications
No indication recorded.